Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat

References

• Ames M. M., Frank S. K. Stereochemical aspects of para-choloramphetamine metabolism. Rabbit liver microsomal metabolism of RS, R(-)-, and S(+)-para-chloroamphetamine. Biochemical Pharmacology 1982; 31: 5–9
   PubMed Web of Science ®Google Scholar
• Anders M. W., Ratnayake J. H., Hanna P. E., Fuchs J. A. Thioredoxin-dependent sulfoxide reduction by rat renal cytosol. Drug Metabolism and Disposition 1981; 9: 341–348
   Google Scholar
• Ariens E. J., Wuis E. W., Veringa E. J. Stereoselectivity of bioactive xenobiotics. A pre-pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochemical Pharmacology 1988; 37: 9–18
   PubMed Web of Science ®Google Scholar
• Aymard C., Seyer L., Cheftel J. C. Enzymatic reduction of methionine sulfoxide. In vitro experiments with rat liver and kidney. Agricultural and Biochemical Chemistry 1979; 43: 1869–1872
   Google Scholar
• Butler B. T., Silvey G., Houston D. M., Borcherding D. R., Vaughn V. L., McPhail A. T., Radzik D. M., Wynberg H., Hoeve W. T., Echten E. V., Ahmed N. K., Linnik M. D. The resolution, isolation, and pharmacological characterization of enantiomers of a benzamide containing a chiral sulfoxide. Chirality 1992; 4: 155–162
   PubMedGoogle Scholar
• Caldwell J. The importance of stereochemistry in drug action and disposition. Journal of Clinical Pharmacology 1992; 32: 925–929
   PubMed Web of Science ®Google Scholar
• Campbell D. B. Stereoselectivity in clinical pharmacokinetics and drug development. European Journal of Drug Metabolism and Pharmacokinetics 1990; 15: 109–125
   PubMed Web of Science ®Google Scholar
• Cho A. K., Wright J. Pathway of metabolism of amphetamine and related compounds. Life Sciences 1978; 22: 363–372
   PubMed Web of Science ®Google Scholar
• Cowley A. J., Wynne R. D., Hampton J. R. The effect of BTS 49 465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers. Hypertension 1984; 2: 547–549
   Google Scholar
• Delatour P., Benoit E., Besse S., Boukraa A. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dog and rats. Xenobiotica 1991; 21: 217–221
   PubMed Web of Science ®Google Scholar
• Delatour P., Benoit E., Caude M., Tambute A. Species differences in the generation of the chiral sulfoxide metabolite of albendazole in sheep and rats. Chirality 1990; 2: 56–160
   Google Scholar
• Drayer D. E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in human: an overview. Clinical Pharmacology and Therapeutics 1986; 40: 125–33
   PubMed Web of Science ®Google Scholar
• Duggan D. E., Hooke K. F., Noll R. M., Hucker H. B., Arman C. G. Comparative disposition of sulindac and metabolites in five species. Biochemical Pharmacology 1978; 27: 2311–2320
   PubMed Web of Science ®Google Scholar
• Fukazawa H., Tomisawa H., Ichihara S., Tateishi M. Purification and properties of methyl sulfoxide reductase from rat kidney. Archives of Biochemistry and Biophysics 1987; 256: 480–489
   PubMedGoogle Scholar
• Hoffman K. J. Identification of main urinary metabolites of omeprazole after an oral dose to rats and dogs. Drug Metabolism and Disposition 1986; 14: 341–348
   PubMedGoogle Scholar
• Jamali F., Mehvar R., Pasutto F. M. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. Journal of Pharmaceutical Sciences 1989; 78: 695–715
   PubMed Web of Science ®Google Scholar
• Kashiyama E., Odomi M., Shimizu T. Stereospecific and simultaneous high performance liquid chromatographic assay of flosequinan and its metabolites in human plasma. Journal of Chromatography 1994; 652: 179–185
   PubMedGoogle Scholar
• Lawton M. P., Philpot R. M. Molecular genetics of the flavin-dependent monooxygenase. Pharmacogenetics 1993; 3: 40–44
   PubMedGoogle Scholar
• Levi P. E., Hodgson E. Stereospecificity in the oxidation of phorate and phorate sulphoxide by purified FAD-containing mono-oxygenase and cytochrome P-450 isozymes. Xenobiotica 1988; 18: 29–39
   PubMed Web of Science ®Google Scholar
• Mondot S., Mestre M., Cavero I. Potassium activation mediates systemic and regional vasorelaxant effects of RP-52891 and nicorandil. European Journal of Pharmacology 1990; 183: 1326–1327
   Google Scholar
• Nelson D. R., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okada K., Nebert D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology 1993; 12: 1–51
   PubMed Web of Science ®Google Scholar
• Renwick A. G., Evans S. P., Sweatman T. W., Cumberland J., George F. The role of the gut flora in the reduction of sulphinpyrazone in the rat. Biochemical Pharmacology 1982; 31: 2649–2656
   PubMed Web of Science ®Google Scholar
• Renwick A. G., Strong H. A., George C. F. The role of the gut flora in the reduction of sulphoxide containing drugs. Biochemical Pharmacology 1986; 35: 64
   PubMed Web of Science ®Google Scholar
• Scheline R. R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacological Reviews 1973; 25: 451–523
   PubMed Web of Science ®Google Scholar
• Sebe T., Saito S., Nishiuchi T., Odomi M., Kaji K., Shimizu T. Haemodynamics and pharmacokinetics of flosequinan after single and multiple oral administration in healthy volunteers. Japanese Journal of Clinical Pharmacology and Therapeutics 1991; 22: 593–600
   Google Scholar
• Sim M. F., Yates D. B., Parkinson R., Cooling M. J. Cardiovascular effect of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. British Journal of Clinical Pharmacology 1988; 94: 371–380
   Google Scholar
• Williams K., Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333–354
   PubMed Web of Science ®Google Scholar
• Wynne R. D., Crampton E. L., Hind I. D. The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers. European Journal of Clinical Pharmacology 1985; 28: 659–664
   PubMedGoogle Scholar
• Yates D. B. Pharmacology of flosequinan. American Heart Journal 1991; 121: 974–983
   PubMedGoogle Scholar
• Yoshihara S., Tatsumi K. Guinea pig liver aldehyde oxidase as a sulfoxide reductase: its purification and characterization. Archives of Biochemistry and Biophysics 1985; 242: 213–224
   PubMed Web of Science ®Google Scholar